Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry. Novavax stock ...

PR Newswire • 16 days ago Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized ... Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value ...

Gaithersburg, Maryland-based Novavax received ... it struck a $1.2 billion licensing agreement with French drugmaker Sanofi to co-commercialize the combination vaccine. Get breaking news and ...

Sanofi, RadioMedix and Orano Med have entered into an exclusive licensing agreement worth €320m to develop a next-generation ...

Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S. Novavax's vaccine is the only protein-based option available in the U.S. for use in ...

Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...

Novavax geht davon aus, dass die vorgefüllten Spritzen an Tausenden Standorten in den USA erhältlich sein werden. Der Impfstoff von Novavax ist die einzige proteinbasierte Option, die in den USA für ...

As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage ...

Novavax (NASDAQ:NVAX), Sanofi (NASDAQ:SNY) – Novavax closed a $1.4 billion deal with Sanofi to commercialize its Covid-19 vaccine and ... it aims to close data licensing deals and explore ...